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Impact of Familial Hypertrophic Cardiomyopathy-Linked Mutations in
the N-Terminus of the RLC on b-Myosin Cross-Bridge Mechanics
Gerrie P. Farman1, Priya Mutha2, Katarzyna Kazmierczak2,
Danuta Szczesna-Cordary2, Jeffery R. Moore1.
1Boston University, Boston, MA, USA, 2Miami University, Miami, FL, USA.
Familial Hypertrophic Cardiomyopathy (FHC) is associated with mutations in
sarcomeric proteins of which myosin regulatory light chain (RLC) is included.
Here we studied the impact of the N-terminal FHC mutations on the molecular
mechanism of b-Myosin heavy chain cross-bridge mechanics using the in vitro
motility assay. To generate mutant b-Myosin, native pig RLC was depleted
from porcine cardiac myosin heavy chain and reconstituted with mutant
(A13T, F18L & E22K) or wild-type human RLC. We characterized the mutant
myosin force and motion generation capability in the presence of a frictional
load and thin filament regulatory proteins. All three mutants exhibited reduc-
tions in maximal filament velocity when tested with both calcium-regulated
(40.5% 5 1.07, 28.9% 5 1.11, & 24.5% 5 1.14 A13T, F18L & E22K
resp.) and unregulated filament (34.4% 5 0.8, 19.1% 5 0.9 & 5.6% 5 0.9
resp.) compared to wild-type. Furthermore, all three mutants displayed reduc-
tions in calcium sensitivity (pCa 50) (~5.13%, ~6.52% & ~4.50% resp.) as well
as cooperative activation (~22%, ~42% & ~34% resp.) of regulated velocity.
These results suggest that the known FHC mutants on the N-terminus of the
RLC affect formation of strong binding cross-bridges thereby reducing maxi-
mal force production. This work is supported by grants to the following people
HL077280 (JM) HL071778 (D S-C).
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The Effect of Regulatory Light Chain Phosphorylation on Myosin Bearing
Familial Hypertrophic Cardiomyopathy-Linked Mutations
Anastasia Karabina1, Priya Muthu2, Katarzyna Kazmierczak2,
Danuta Szczesna-Cordary2, Jeffrey Moore1.
1Boston University School of Medicine, Boston, MA, USA, 2University of
Miami School of Medicine, Miami, FL, USA.
Familial Hypertrophic Cardiomyopathy (FHC) is characterized by hypertro-
phy of the left ventricle that can often be preceded by diastolic dysfunction.
The clinical presentation of the disease varies widely from asymptomatic to
progressive heart failure to sudden cardiac death. FHC is caused by mutations
in 1 of the 14 genes that encode for sarcomeric proteins. Two FHC mutations,
N47K and R58Q, located in the regulatory light chain (RLC) of myosin have
previously been shown to reduce actin filament velocity under load, stemming
from a more compliant lever arm (Greenberg et al., PNAS add details 2010).
The RLC mechanically stabilizes the neck/lever arm of myosin, which is
crucial to myosin’s ability to transmit contractile force. Phosphorylation of
the RLC can impart stiffness to the myosin lever arm. In the work presented
here, in vitro motility assays are utilized to investigate the effects of RLC
phosphorylation on the FHC RLC mutant phenotype in the presence of an
a-actinin frictional load. When co-incubated with a 0.5 mg/ml a-actinin fric-
tional load, the R58Q mutation reduces actin sliding velocity to 54% of WT
values, consistent with previous findings that myosin bearing the R58Q muta-
tion exhibits reduced force production. Phosphorylation of R58Q mutant
myosin restored velocity to 68% of WT velocity. These results suggest that
that RLC phosphorylation may have a minor inhibitory effect on the FHC
phenotype at the molecular level. Supported by AHA- 12PRE11910009
(AK), 10POST3420009 (PM), NIH- HL071778 & HL090786 (DSC) and
HL077280 (JM).
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Effects of Hcm-LinkedMutations in Myosin Essential Light Chain and the
Role of Serine-195 Pseudo-Phosphorylation
Wenrui Huang, Kartarzyna Kazmierczak, Priya Muthu,
Danuta Szczesna-Cordary.
University of Miami, Miami, FL, USA.
In this study we investigated whether phosphorylation of myosin ELC at Serine
195, identified by proteomic analysis as a novel phosphorylation site, and
shown to affect contractility in zebrafish cardiomyocytes, can play a role in
cardiac muscle contraction. We also investigated whether S195D pseudo phos-
phorylation of ELC could rescue an ELC induced hypertrophic cardiomyopa-
thy (HCM) phenotype. To test this, we exchanged human recombinant
WT-ELC, WT-S195D and ELC-A57G, E143K and M173V mutants in skinned
porcine papillary muscle fibers and porcine cardiac myosin, both expressing the
b-myosin heavy chain (MHC). In myosin exchange experiments, we observed
a stronger binding of WT-S195D to MHC (lower Kd), but the degree of ELC
exchange vs. WT was significantly lower (~48% vs. ~69%). However, no
changes in %-reconstitution were observed among all recombinant ELC mu-tants when compared to WT. In the ELC-reconstituted fibers, WT-S195D
was seen to exchange with a significantly lower efficiency compared with
WT (~33% vs 47%), but it also caused a small increase in maximal force (by
~3 kN/m2). An increase in maximal tension upon pseudo-phosphorylation of
ELC was in accord with the MLCK-induced or pseudo (with S15D
mutation)-phosphorylation observed for the myosin RLC. However, a WT-
S195D-mediated increase in force was not accompanied by any increase in
myofilament calcium sensitivity, as observed in RLC studies. Maximal force
generation was not changed in any of ELC-reconstituted fibers when compared
to WT-ELC. Two ELC mutants (A57G and E143K) slightly (but significantly)
increased Ca2þ-sensitivity of force while M173V produced no change. Further
studies are needed to reveal whether these subtle changes seen in A57G
and E143K-exchanged porcine cardiac preparations could be ‘‘rescued’’ by
respective S195D pseudo-phosphorylation mimics. Supported by AHA-
12PRE12030412 (WH) and NIH-HL108343 (DSC).
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Priya Muthu1, Wenrui Huang1, Katarzyna Kazmierczak1, Jingsheng Liang1,
Ana Isabel Rojas1, Thomas Irving2, Danuta Szczesna-Cordary1.
1University Of Miami: Miller School of Medicine, Miami, FL, USA, 2Illinois
Institute of Technology, Chicago, IL, USA.
The current study is aimed at providing insight into the structural defects un-
derlying the development of malignant phenotypes induced by D166V and
R58Q mutations in the regulatory light chain (RLC) of myosin. X-ray diffrac-
tion studies were carried out on the freshly skinned papillary muscle fibers
from transgenic mutant vs. wild-type mice using the small angle instrument
on the BioCAT beamline 18-D at the Advanced Photon Source. The fiber
was immersed in relaxing solution and the X-ray measurements were made
at two sarcomere lengths (SL), short (~2.3 mm) and long (~2.5 mm). At the
short SL, we observed that the R58Q mutation caused a significant increase
in the interfilament lattice spacing (d1,0) compared to Tg-WT while no change
was observed for the D166V mutation. Interestingly, upon stretch to long SL,
WT and R58Q showed a significantly decreased lattice spacing (by ~1.5 nm)
while the d1,0 in the D166V myocardium remained the same as measured at
short SL. The lack of structural response to stretch observed for D166V may
indicate a mutation induced increase in fiber stiffness. In support of this
notion, measurements of passive force performed in glycerinated skinned
papillary Tg-D166V fibers demonstrated significantly increased levels of
passive tension at all points of stretch (10%, 20%, 30% and 40% of fiber
length) indicating an elevated resistance to stretch in Tg-D166V compared
to Tg-WT fibers. Our results suggest that the mutant-induced structural
changes that most likely trigger pathological remodeling of the heart leading
to FHC are different for both studied RLC mutations. Supported by AHA-
10POST3420009 (PM), NIH- HL071778 (DSC), HL090786 (DSC), P41
GM103622-17 (TI)
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Volume Overload Heart Failure Increases Myocardiac Passive Stiffness
in a Mouse Model
Kirk Hutchinson, Charles Chung, Chandra Saripalli, Carlos Hidalgo,
Henk Granzier.
University of Arizona, Tucson, AZ, USA.
Volume overload (VO) heart failure occurs due to pathologies such as mitral
valve regurgitation, infarcts and ventricular septal defects, and leads to charac-
teristic eccentric dilation. Changes in passive myocardial stiffness are not well
understood and here we dissected the contribution of extracellular matrix
(ECM)-based and titin-based stiffness to overall passive stiffness. Titin is a gi-
ant protein that regulates passive tension and hence diastolic function in the
myocardium. In heart failure, differential splicing and phosphorylation events
can occur that alter the stiffness of this protein and influence hemodynamics.
Increased diastolic stiffness due to differential splicing and phosphorylation
of titin has been observed in pressure overload hypertrophy; however, there
are no published studies investigating whether pure LV VO during compen-
sated heart failure leads to changes in titin based passive stiffness. We studied
the role of titin in modulating diastolic function in VO induced by aortocaval
fistula (ACF) in the mouse. ACF was induced in three-month-old male
C57BL/6 animals and allowed to progress for 4 weeks. At 4 weeks, echocardi-
ography confirmed the presence of eccentric dilation and decreased systolic
function as expected. Tissues mechanics indicated an increase in titin, which
correlated with a significant decrease in N2BA/N2B ratio. ECM based passive
stiffness was unchanged in VO. In summary, VO causes an increase in titin
based passive stiffness.
